UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.	38345-174995

First Inventor Han-Mo KOO and George F. VANDE WOUDE

INHIBITION OF MITOGEN-ACTIVIATE PROTEIN KINASE (MAPK) PATHWAY: A SELECTIVE THERAPEUTIC STRATEGY AGAINST MELAONMA

(Unly for n	iew nonprovisiona	il applications under 3	7 C.F.R. 1.53(b))	Express Mail L	.abel IVo.					
APPLICATION ELEMENTS					ESS TO).		ssistant Commissioner for Patents		
See MPEP chapter 600 concerning utility patent application contents.				ADDI						
1. \(\) \(Fee Transmittal Submit an original ar Applicant claims See 37 CFR 1.2 Specification preferred arrange Descriptive title o Cross Reference Statement Regar Reference to seq or a computer pro Background of th Brief Summary of Brief Description Detailed Description	B/17) essing) I Pages 60] ns & D	8. Nucle (<i>if ap</i> a. b. Spe i. ii. [Washington, DC 20231 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATIONS PARTS 9. Assignment Papers (cover sheet & document(s))						
- Claim(s) - Abstract of the Disclosure 4. Drawing(s) (35 U.S.C.113) [Total Sheets 16] 5. Oath or Declaration [Total Pages 2] a. UNEXECUTED (original or copy) b. Copy from a prior application (37 CFR 1.63 (d))				13.	11. ☐ English Translation Document (if applicable) 12. ☐ Information Disclosure ☐ Copies of IDS Statement (IDS)/PTO-1449 Citations 13. ☐ Preliminary Amendment 14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent					
19. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Prior application information: Examiner Group / Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 20. CORRESPONDENCE ADDRESS Customer Number or Bar Code Label According to provide the requisite information below and in a preliminary amendment, or in an Application No. CIP OF Prior application No. Group / Art Unit: The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. CORRESPONDENCE ADDRESS Or Correspondence address below Application No. Correspondence address below Application No. Correspondence address below										
Name	VENABLE	a second to the								
Address										
City	Washington	n State		D.C.	D.C. Zin		Code	20043-9998		
Country	U.S.A		Telephone	202-962-48	00	-	Fax	202-962-8300		
			Registration	Registration No. (Attorney/Ager			33,949			
Signature			<u></u>	Date August 31, 2						

#313944 v1 - transmittal sheet for US app PC Docs No.

